Foresee Pharmaceuticals (6576.TWO), a Taiwan and United States-based biopharmaceutical company, announced on Thursday that it has signed an exclusive license agreement with Intas Pharmaceuticals for the commercialisation of Foresee's novel FP-001 program, Leuprolide Mesylate Injectable Suspension ready-to-use subcutaneous six-month and three-month depot formulations (Camcevi) in the United States.
According to the terms of the collaboration, Foresee Pharmaceuticals will receive USD10m upfront, along with certain regulatory milestones and sales milestones payments having a combined value totalling up to USD207m and a share of the product revenue in the territory. Accord BioPharma, Inc, a United States affiliate of Intas, is to cover all commercialisation costs in the territory.
The company has not filed the three-month indication for Camcevi with the US Food and Drug Administration (FDA), which is under development by Intas and Foresee, the Section 505(b)(2) New Drug Application for the six-month Camcevi indication, is presently under review by the US FDA.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT